Androgen receptor expression and its prognostic value in T1N0 luminal/HER2-breast cancer

Wenjing Zhong,Jiarong Yi,Haoming Wu,Xuxiazi Zou,Jikun Feng,Xinjian Huang,Siqi Li,Xi Wang
DOI: https://doi.org/10.2217/fon-2021-1300
2022-01-01
Future Oncology
Abstract:Purpose: The authors aimed to evaluate the prognostic and predictive value of androgen receptor (AR) expression in patients with luminal/human EGFR2 negative (HER2-) T1N0 breast cancer. Methods: The cohort in this retrospective study comprised 471 patients with luminal/HER2- T1N0 breast cancer who had undergone surgery between 2013 and 2017 in the authors' center. Results: Androgen receptor (AR)+ tumors were associated with favorable characteristics. AR+ patients had better 5-year recurrence-free survival rates and the risk of recurrence was greater for AR- than for AR+ patients. AR- status predicted the failure of adjuvant endocrine therapy with aromatase inhibitors and of adjuvant chemotherapy with docetaxel plus cyclophosphamide. Conclusion: AR+ expression is significantly related to a better prognosis. AR expression may be an additional biomarker for both endocrine and chemotherapy responsiveness.
What problem does this paper attempt to address?